ESPR
Esperion Therapeutics, Inc.
1.19
USD
This page is just a preview of the data found in TrendSpider’s full version
Esperion Therapeutics, Inc. stock is up 42.77% since 30 days ago. The next earnings date is Feb 20, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 63.64% of the previous 10 November’s closed higher than October. In the last 1 Unusual Options Trades, there were 1 PUT. 67% of analysts rate it a buy.
| Date & Time | Expiration Date | Strike Price | Trade Type | Size | Open Interest |
|---|---|---|---|---|---|
| 04 Oct 19:47 | 21 Jun, 2024 | 5.00 | 1687 |
Esperion Therapeutics, Inc. develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. The company has a license and collaboration agreement with Daiichi Sankyo Europe GmbH; and Serometrix to in-license its oral, small molecule PCSK9 inhibitor program.
